Duman, Serkan http://orcid.org/0000-0002-3144-8671
Kuru, Digdem
Gumussoy, Mesut
Kiremitci, Saba
Gokcan, Hale
Ulas, Bahar
Ellik, Zeynep
Ozercan, Mubin
Er, Ramazan Erdem
Karakaya, Fatih
Bodakci, Emin
Erden, Ayse
Elhan, Atilla H.
Savas, Berna
Loomba, Rohit
Idilman, Ramazan
Article History
Received: 4 September 2023
Revised: 4 September 2023
Accepted: 5 October 2023
First Online: 21 November 2023
Declarations
:
: The scientific guarantor of this publication is Ramazan Idilman.
: For all authors, except Rohit Loomba, there are none to declare conflicts of interest, no financial support was received for the conduct of this study. Rohit Loomba serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bios, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institutions received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc.Ramazan Idilman is a member of the Science Academy.
: One of the authors (Atilla H Elhan) has significant statistical expertise.
: Written informed consent was waived by the Institutional Review Board.
: This study was approved by the ethics committee of the Ankara University School of Medicine.
: None of these study subjects were previously reported.
: • Retrospective• Diagnostic or prognostic study• Performed at one institution